Company intelligence / Profile preview
Relay Therapeutics
Cambridge, Massachusetts, United Statesrelaytx.com ↗
- Ownership
- Public · RLAY
- Employees
- ~500
- Development stage
- Phase 2
01
Overview
Advancing multiple programs including RLY-2608 (first-in-class mutant-selective PI3Kα inhibitor) which has shown lesion regressions in experimental models of PIK3CA-related vascular malformations, and other candidates in various clinical stages[4]
- Therapeutic areas
- Rare DiseasesOncologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Elevar Therapeutics (global outlicense for Lirafugratinib/RLY-4008)[4]
04
Financials
- Market cap
- $3.7B
- Total revenue
- $15.4M
- Enterprise value
- $2.9B
Beyond the preview
Go deeper on Relay Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Relay Therapeutics.